Associate Director, Portfolio Strategy & Analytics
- Employer
- Intellia Therapeutics
- Location
- Cambridge, MA, United States
- Start date
- May 1, 2021
View more
- Discipline
- Marketing, Strategic Marketing
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Genetown
Job Details
At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for immuno-oncological and autoimmune diseases.
Job Description:
Summary:
Reporting to the VP of Strategy and Portfolio Management, the Associate Director of Portfolio Strategy and Analytics will work cross-functionally, with executive, functional and program leadership, to define and support the implementation of Intellia's portfolio strategy.
The breadth and modularity of Intellia's CRISPR/Cas9 gene editing platform enables an incredible number of potential opportunities to develop transformative therapeutics, highlighting the importance of informed portfolio decision-making. As a result, this is a high-impact role that will play a critical part in defining the evolution of Intellia's pipeline, including both in vivo and ex vivo therapies.
Key Responsibilities:
- Develop and implement analytical frameworks and modeling approaches to support strategic decision-making and overarching portfolio strategy
- Partner with program and functional leadership to develop assumptions required to support portfolio modeling and analytics
- Establish and implement overarching portfolio strategy and prioritization in collaboration with cross-functional leadership
- Conduct business case analyses / provide analytical support for emerging pipeline and platform program teams
- Develop analytics to support long-range planning in collaboration with finance and program management
- Collaborate with / support business development to assess and guide opportunities consistent with corporate strategy
Qualifications:
- 8+ years' work experience in equity research, consulting, investment banking, and/or industry
- Ability to develop and implement advanced portfolio analytics, revenue forecasts, and valuation models required
- Ability to work effectively in matrixed organization
- Demonstrated ability to communicate with and influence stakeholders with diverse range of expertise
- Strong verbal and written communication skills, as well as comfort presenting to executive audiences
- Experience with market analytics, market research, and competitive intelligence preferred
- BA/BS required, PhD and/or MBA preferred
#LI-SV1
EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Company
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
- Website
- http://intelliatx.com/
- Phone
- (857) 285-6200
- Location
-
40 Erie Street
Cambridge
Massachusetts
02139
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert